Word

CELLVIE

Status

Dead

Status Code

602

Status Date

Friday, December 17, 2021

Serial Number

79288683

Mark Type

3

Filing Date

Wednesday, February 26, 2020

Abandoned Date

Tuesday, December 7, 2021

Trademark Owner History

cellvie Inc. - 1st New Owner Before Publication
Cellvie UG (haftungsbeschränkt) - Original Applicant

Classifications

5 Preparations for medical purposes employing mitochondria; cardiovascular treatment preparations employing mitochondria; cardiovascular pharmaceuticals employing mitochondria used in treating arrhythmias; pharmaceutical and biological preparations for the treatment of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies, tumors or diabetes mitochondria for transplant purposes for medical use; pharmaceutical and biological preparations for the application of mitochondria transplantation for medical purposes in vessel and organ transplantations; implantable living tissue and mitochondria for the promotion of tissue growth, for medical use; mitochondria, for medical use; biological tissue cultures containing mitochondria for medical purposes; pharmaceutical and biological preparations containing mitochondria for tissue regeneration and protection for medical purposes; living cell components, namely, mitochondria, including genetically-modified mitochondria or pharmaceutically treated mitochondria, for medical use in humans and veterinary use in animals

44 Medical testing services for diagnostic and disease treatment purposes relating to cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors; medical analysis of human or animal tissues for mitochondria transplant treatment purposes of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors; medical analysis of cells and cell components in relation to mitochondria for diagnostic and treatment purposes of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors

10 Prosthetic tissues based on mitochondria for parietal, vascular and visceral use; medical apparatus and devices for the processing of tissue- or cell-samples for the isolation of mitochondria or other cell components, namely, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles from muscle tissue or other human or animal tissues, as well as from cells and cell cultures; filter for the isolation of cell components, namely, mitochondria, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles from cells for medical purposes; medical apparatus and devices for the transplantation or injection of cells or cell component, namely, mitochondria, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles in humans or animals

42 Scientific and technological services, namely, scientific and clinical research, analysis and testing in the field of mitochondrial isolation or transplantation; scientific and clinical research and development services in the field of mitochondria; conducting clinical trials for others in the field of cardiovascular diseases, ischemia-and reperfusion-injuries, heart transplantations, tumor treatments, mitochondrial myopathies analysis of human tissues for scientific and clinical research relating to mitochondria; scientific and clinical research, analysis and testing services relating to the isolation and cultivation of human and animal mitochondria

The mark consists of multiple blue dots, being light blue in the middle and getting progressively darker toward the outside, some connected with curved lines, forming a spiral shape. The word "CELLVIE" sits underneath the spiral in grey.
The color(s) blue, light blue and grey is/are claimed as a feature of the mark.

Trademark Events

Jul 2, 2020

Sn Assigned For Sect 66a Appl From Ib

Jul 9, 2020

New Application Office Supplied Data Entered

Jul 9, 2020

Assigned To Examiner

Jul 14, 2020

Application Filing Receipt Mailed

Jul 15, 2020

Non-Final Action Written

Jul 16, 2020

Non-Final Action (Ib Refusal) Prepared For Review

Aug 25, 2020

Refusal Processed By Mpu

Sep 5, 2020

Non-Final Action Mailed - Refusal Sent To Ib

Sep 27, 2020

Refusal Processed By Ib

Dec 22, 2020

Teas Response To Office Action Received

Mar 26, 2021

Assigned To Lie

Mar 29, 2021

Correspondence Received In Law Office

Mar 29, 2021

Teas/Email Correspondence Entered

Jun 5, 2021

Final Refusal Written

Jun 5, 2021

Final Refusal E-Mailed

Jun 5, 2021

Notification Of Final Refusal Emailed

Dec 8, 2021

Notification Of Possible Opposition Created, To Be Sent To Ib

Dec 8, 2021

Notification Of Possible Opposition Sent To Ib

Dec 17, 2021

Abandonment - Failure To Respond Or Late Response

Dec 17, 2021

Abandonment Notice E-Mailed - Failure To Respond

Dec 25, 2021

Notification Of Possible Opposition - Processed By Ib

Dec 17, 2022

Final Disposition Notice Created, To Be Sent To Ib

Dec 19, 2022

Final Disposition Notice Sent To Ib

Jan 9, 2023

Final Decision Transaction Processed By Ib

Sep 20, 2024

Change Of Owner Received From Ib